Several studies have suggested that elevated circulating IGF-1 confers negative prognostic significance, both in unselected breast cancer populations [57] and in women undergoing endocrine therapy, where IGF-1 activation has been linked to therapeutic resistance and disease progression [57,58]. This evidence concerns the gene IGF1 and breast carcinoma.